Jefferies puts Shire on hold

Jefferies & Co., Inc. analyst Robin Campbell rated Shire plc at hold following the company's settlement with Barr. According to the analyst, Shire's NRP104 has a better chance as the new, innovator ADHD product. Jefferies is reviewing its rating of Shire as the components of the Barr deal are complex and are subject to approval. Shares of the Basingstoke, England-based pharmaceutical company were up $1.48, or 3.01%, at $50.71 on volume of 5,404,224 shares versus the three-month running average of 553,881 shares. (Nasdaq: SHPGY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.